Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Japanese Pharma Companies Start Voluntary Recall Of Heparin

This article was originally published in PharmAsia News

Executive Summary

Japan's Ministry of Health, Labor and Welfare announced that Osaka-based Fuso Pharmaceutical, Tokyo-based Terumo Corp. and Tokushima-based Otsuka Pharmaceutical have begun recalling 17 heparin products. American drug maker Baxter Healthcare's heparin has been linked to severe side effects, including 21 deaths. The three Japanese companies use the same active ingredient for heparin as Baxter, which is imported from American company Scientific Protein Laboratories and made from materials in China. In Japan, 70 percent to 80 percent of the 270,000 dialysis patients use heparin, and Fuso and Otsuka products combined account for 50 percent of the heparin market. (Click here for more - Japanese language

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067892

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel